• For Patients
• Important Safety Information
• AstraZeneca Web Sites

• Home
• About ZOMIG
  • Fast Headache Response
  • Pain-free Response
  • Formulation Options
  • Prescribing Information
• HCP Resources
• Patient Resources
• Virtual Rep
• 

The Power: PAIN-FREE RESPONSE^2-4,8—across all 3 formulations.

Each formulation of ZOMIG (zolmitriptan)—ZOMIG^® Tablets, ZOMIG-ZMT^® (zolmitriptan) and ZOMIG^® Nasal Spray—has the power to deliver a pain-free response, providing today’s patient with the migraine pain relief she needs to live her demanding, double-day life at work and at home without migraines.

• Pain-free response is defined as a reduction in headache pain from severe or moderate intensity to no pain.
• From a multicenter, double-blind, placebo-controlled, dose range–finding study of ZOMIG Tablets 2.5 mg (n=260) and 5 mg (n=245) vs placebo (n=121) for the treatment of severe or moderate migraine headache.

• Pain-free response is defined as a reduction in headache pain from severe or moderate intensity to no pain.
• From a multicenter, double-blind, randomized, placebo-controlled study of ZOMIG-ZMT 5 mg (n=245) vs placebo (n=341) for the treatment of moderate or severe migraine.³

• Pain-free response is defined as a reduction in headache pain from severe or moderate intensity to no pain.
• From a multicenter, randomized, double-blind, parallel-group trial (n=1868) with ZOMIG Nasal Spray 5 mg vs placebo, treating up to 2 migraine attacks of moderate or severe intensity. The primary end point was headache response at 15 and 30 minutes, 1 and 2 hours after initial treatment. Secondary end points included pain-free rates at all time points and 24-hour sustained headache response and pain-free rates.⁹

Important Safety Information

ZOMIG is indicated for the acute treatment of migraine with or without aura in adults, where a clear diagnosis of migraine has been established.

ZOMIG is not intended for the prophylactic therapy of migraine and is not indicated for the treatment of cluster headache.

• ZOMIG is contraindicated in patients with
  • Ischemic heart disease (eg, silent ischemia, angina), coronary artery vasospasm, or other significant underlying cardiovascular disease
  • Cerebrovascular syndromes (eg, history of stroke or TIA)
  • Peripheral vascular disease (eg, ischemic bowel disease)
  • Uncontrolled hypertension
• Use of ZOMIG is contraindicated within 24 hours of another 5-HT₁ agonist, ergotamine-containing or ergot-type medication, or within 2 weeks of an MAO-A inhibitor
• ZOMIG should not be administered to patients with hemiplegic or basilar migraine
• It is strongly recommended that ZOMIG not be given to patients in whom unrecognized coronary artery disease (CAD) is predicted by the presence of risk factors without a satisfactory cardiac evaluation
• Patients with symptomatic Wolff-Parkinson-White syndrome or arrhythmias associated with other accessory cardiac conduction pathways should not receive ZOMIG
• Development of a potentially life-threatening serotonin syndrome may occur with triptans particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)
• Phenylketonuric patients should be informed that ZOMIG-ZMT^® (zolmitriptan) contains phenylalanine
• ZOMIG should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus
• Side Effects: The most common adverse reactions in clinical trials for ZOMIG and ZOMIG-ZMT were paresthesia, asthenia, nausea, dizziness, pain, chest or neck tightness or heaviness, somnolence, and warm sensation
• Side Effects: The most common adverse reactions in clinical trials for ZOMIG Nasal Spray were unusual taste, paresthesia, hyperesthesia, and dizziness